Profile
Winnie completed her specialist training in nuclear medicine in 2009 and has since been contributing actively in the various aspects of clinical service, education and research. Notably, she was the inaugural Program Director of the SingHealth Nuclear Medicine Residency (2012 to 2018). She was instrumental in establishing and developing the programme, leading it to achieve the award of Best JCST Programme in SingHealth in 2018. Winnie also served as the Director of NM Ops and as a member on various committees such as the Cluster RISPACS Steering Committee and the MOH Residency Advisory Committee. She was the Vice Chair, Chapter of Nuclear Medicine, College of Radiologists, Academy of Medicine Singapore (2013 to 2021).
Education
Fellow of the Academy of Medicine, Singapore in
Nuclear Medicine, 2010
Fellow of the Royal College of Radiologists (UK), 2007
MBBS, National University of Singapore, 2002
View More +
Professional Appointments and Committee Memberships
- Academic Deputy Vice Chair, Clinical Service Operations, Radiological Sciences Academic Clinical Programme, SingHealth Duke-NUS Academic Medical Centre
- Member, Radiological Sciences SingHealth Executive Committee
- Member, Residency Advisory Committee for Nuclear Medicine, Ministry of Health
View More +
Awards
- Silver Award, SGH Team Excellence IQC Assessment by SIngapore Productivity Association 2016
- Outstanding Faculty Award, Residency in SingHealth Excels (RiSE) Award, 2013-14
View More +
Research Interests
Nuclear medicine
Molecular Imaging
View More +
Publications
- Ng CWQ, Bin Hassan MJ, Goh C, Tong AKT, Tham WY, Thang SP, Lam WW, Low HC, Magsombol BM, Loke KSH. Safety and Efficacy of 90Y Selective Internal Radiation Therapy Using Glass Microspheres in Hepatocellular Carcinoma: A Southeast Asian Single-Institution Initial Experience. J Nucl Med Technol. 2024 Jun.
- Chin J, Tan YG, Lee A, Ng TK, Shi R, Tang CYL, Thang SP, Tuan JKL, Cheng CWS, Tay KJ, Ho HSS, Wang H, Chiu PK, Teoh JY, Lam WW, Law YM, Yuen JSP, Chen K. “See Is Believing”: Additive Utility of 68Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis. Cancers (Basel). 2024 May.
- Tay WJ, Teh DJW, Qin Y, Lam WW. The Curious Case of the Missing Limb on FDG PET Imaging. Clin Nucl Med. 2024 Feb.
- Tang CYL, Chua WM, Huang HL, Lam WW, Loh LM, Tai D, Ong SYK, Yan SX, Loke KSH, Ng DC, Tham WY. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. J Neuroendocrinol. 2023 Dec.
- Tang CYL, Lim GKY, Chua WM, Ng CWQ, Koo SX, Goh CX, Thang SP, Zaheer S, Lam WWC, Huang HL. Optimization of Bayesian penalized likelihood reconstruction for 68 Ga-prostate-specific membrane antigen-11 PET/computed tomography. Nucl Med Commun. 2023 Jun.
- Sommat K, Tong AKT, Ong ALK, Hu J, Sin SY, Lam WWC, Xie W, Khor YM, Lim C, Lim TW, Selvarajan S, Wang F, Tan TWK, Wee JTS, Soong YL, Fong KW, Hennedige T, Hua TC. 18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma. Asia Pac J Clin Oncol. 2023 May .
- Chua WM, Lam WW, Tong AK, Sultana R, Kua SMY, Kanesvaran R, Wong ASC, Tay KJ, Cheng TJL, Ng DCE, Thang SP. Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study). Asia Pac J Clin Oncol. 2023 Mar .
- Chen M, Tang CYL, Fong WWS, Lam WW. Semi-quantitative indices of 2[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response. EJNMMI Res. 2023 Mar.
- Ng DZ, Lee CY, Lam WW, Tong AK, Tan SH, Khoo LP, Tan YH, Chiang J, Chang EW, Chan JY, Poon EY, Somasundaram N, Farid H Rashid M, Tao M, Lim ST, Yang VS. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method. Leuk Lymphoma. 2022 Jan.
- Tang CYL, Chua WM, Cheng LTJ, Fong W, Zaheer S, Lam WW. 18F-FDG PET/CT Manifestations of IgG4-related Disease. Br J Radiol. 2021 Aug.
View More +
Research Trials
- 18F-FET (O-(2-[18F]fluoroethyl)-L-tyrosine) PET
in differentiating tumour progression from pseudoprogression in high grade
gliomas (supported by Khoo Pilot Award (Collaborative)) - as Co-Investigator
- 68Ga-FAPI based PET/CT for imaging Systemic sclerosis-associated Interstitial
Lung Disease (SSc-ILD) (supported by SGH Research Grant) - as Co-Investigator
- Outcomes of Radioiodine Therapy for Thyroid Cancer - as PI
- Scheme for the Discovery of Biomarkers of Toxicity and Efficacy for CAR-T
Cells - as Co-Investigator
- FDG PET/CT in IgG4-related disease - as PI
- Clinical utility of PET imaging in prostate cancer - as PI
- A Phase 4, randomized, open-label, multicenter efficacy and safety study of
standard dose of radium-223 dichloride vs. standard doses of novel
anti-hormonal therapy (NAH) in patients with bone dominant metastatic
castration resistant prostate cancer (mCRPC) progressing on/after one line of
NAH -as Co-Investigator
- Outcomes of Yttrium-90 Trans-arterial Radioembolization (Y90 TARE) - as
Co-Investigator
- Outcomes of peptide receptor radionuclide therapy (PRRT) as Co-Investigator
View More +
